Current Quality of Cardiovascular Prevention for Million Hearts™ An Analysis of 147,038 Outpatients from The Guideline Advantage ™ Zubin J. Eapen, MD,

Slides:

Advertisements

Similar presentations

Investigating Gender Differences in HEDIS Measures Related to Heart Disease Ann F. Chou, PhD, MPH Carol S. Weisman, PhD Rosaly Correa-de-Araujo, MD, PhD.

Advertisements

© 2010, American Heart Association. All rights reserved. Are Quality Improvements Associated with the GWTG-Coronary Artery Disease (GWTG-CAD) Program Sustained.

© 2010, American Heart Association. All rights reserved. A Validated Risk Score for In-hospital Mortality in Patients with Heart Failure from the American.

ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial The telmisartan trial in cardiovascular protection Sponsored by Boehringer.

Hernandez et al. JAMA, May 5, 2010 – Vol. 303, No. 17 Relationship Between Early Physician Follow-up and 30-day Readmission Among Medicare Beneficiaries.

Risks of Intracranial Hemorrhage among Patients with Acute Ischemic Stroke Receiving Warfarin and Treated with Intravenous Tissue Plasminogen Activator.

Connie N. Hess, MD, Bimal R. Shah, MD, MBA, S. Andrew Peng, MS, Laine Thomas, PhD, Matthew T. Roe, MD, MHS, Eric D. Peterson, MD, MPH Relationship of Early.

DISCLOSURE INFORMATION (relative only): Eric D. Peterson, PI of the AHA GWTG Data Analysis Center; Lee H. Schwamm, Chair of the AHA National Steering Committee.

Unplanned 30-Day Readmission Risk Among Patients with Acute Myocardial Infarction: a Report from TRANSLATE-ACS Connie N. Hess, MD 1 ; Tracy Y. Wang, MD,

“Influence of Stroke Subtype on Quality of Care in The Get With The Guidelines-Stroke Program” Eric E. Smith, MD, MPH; Li Liang PhD; Adrian F Hernandez,

PubMed was searched for randomized clinical trials published between 2007 and 2012 in the New England Journal of Medicine (NEJM) Trials were included if.

Trends in the Use of Evidence-Based Treatments for Coronary Artery Disease Among Women and the Elderly Findings From the Get With the Guidelines Quality-

Regional Differences in Quality of Care and Outcomes for the Treatment of Acute Coronary Syndromes: An Analysis from the Get With The Guidelines Program.

Presenter Disclosure Information Paul M Ridker, MD, FACC Dr Ridker is listed as a co-inventor on patents held by the Brigham and Women’s Hospital that.

Are Quality Improvements Associated with the GWTG-Coronary Artery Disease (GWTG-CAD) Program Sustained Over Time? A Longitudinal Comparison of GWTG-CAD.

Quality of Care and In-Hospital Outcomes in Patients With Coronary Heart Disease in Rural and Urban Hospitals (from Get With the Guidelines– Coronary.

Successful Approaches to Reduce Hypertension Stephen Sidney, MD, MPH Kaiser Permanente Northern California October 17, 2012.

Epidemiology of Stroke Dexter L. Morris, PhD, MD Department of Emergency Medicine University of North Carolina School of Medicine Chapel Hill, NC.

 men Differences in Blood Pressure Documentation and Clinical Practice Variability: Implications for Population Management for Hypertension and Opportunities.

1 National trends in rates of death and hospital admissions related to acute myocardial infarction, heart failure and stroke, 1994–2004 CIHR Team Grant.

Health Disparities in Cardiovascular Disease Paula A. Johnson, MD, MPH Chief, Division of Women’s Health; Executive Director, Connors Center for Women’s.

Patients with HF have increased risk for thrombotic events. However, the net clinical benefit of anticoagulation in a HF population in sinus rhythm has.

December Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation?

Background Using the GWTG-Stroke database and the Centers for Medicare & Medicaid Service files, we analyzed Medicare patients with acute ischemic stroke.

Patterns of red blood cell transfusion use and outcomes in patients undergoing percutaneous coronary intervention in contemporary clinical practice: Insights.

How Much AF is Too Much AF? Do I Initiate Anticoagulation Based on AF Detected on Device Monitoring? Kenneth W. Mahaffey, MD, FACC Professor of Medicine,

Predictors of Cardiac Rehabilitation Referral in Coronary Artery Disease Patients: Results From the AHA’s Get With the Guidelines Program Todd M. Brown,

Adherence and Persistence in the Use of Warfarin After Hospital Discharge Among Patients With Heart Failure and Atrial Fibrillation Zubin J. Eapen, Xiaojuan.

” “The Dissociation Between Door-to- Balloon Time Improvement and Improvements in Other Acute Myocardial Infarction Care Processes and Patient Outcomes”

Do Heart Failure Disease Management Programs Make Financial Sense Under a Bundled Payment System? Zubin J. Eapen, Shelby D. Reed, Lesley H. Curtis, Adrian.

Research CDC Standards

Managing Patients Who Cannot Take Anticoagulants Kenneth W. Mahaffey, MD, FACC Professor of Medicine, Cardiology Faculty Associate Director, DCRI Director,

VA National Center for Health Promotion and Disease Prevention Using USPSTF Recommendations in VHA Clinical Practice Linda Kinsinger, MD, MPH Chief Consultant.

RISK STRATIFICATION. Established by the CACR in Sept National Guidelines Committee The committee acknowledged the support of the Canadian Cardiovascular.

Comparison of two cardiovascular risk assessment tools to determine appropriate use of aspirin as primary prevention for patients with type 2 diabetes.

Treatment and Risk in Heart Failure: Gaps in Evidence or Quality? Pamela N. Peterson, MD MSPH; John S. Rumsfeld, MD PhD; Li Liang PhD; Adrian F. Hernandez,

A-1 Introduction Pravastatin-Aspirin 7asdf Fred T. Fiedorek, M.D. Vice President, Clinical Design & Evaluation, Metabolics Pharmaceutical Research Institute.

Impact of Prior Myocardial Infarction Among Patients with Acute Myocardial Infarction Treated in Contemporary Practice: A Report from the ACTION Registry.

Million Hearts Initiative, 2015 IPC Intensive, Million Hearts.

Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic Updates (CMS164) Change Review Process Meeting November 19, 2015 Jenna Williams-Bader.

ENSW PTO Training Clinical Quality Measures Kyle Knierim, MD Using DARTNet to Improve Practice Wilson Pace, MD Kyle Knierim, MD 1.

Smoking Research has shown that smoking increases heart rate, blood pressure, tightens major arteries, and can create irregularities in the timing of.

Antiplatelet Therapy Use after Discharge among Acute Myocardial Infarction Patients with In-hospital Bleeding Tracy Y. Wang, MD, MHS, Lan Xiao, PhD, Karen.

Insights from the PROMISE Trial Neha J. Pagidipati, MD MPH; Kshipra Hemal; Adrian Coles, PhD; Daniel B. Mark, MD MPH; Rowena J. Dolor, MD MHS; Patricia.

The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: AACVPR/ACC/AHA 2007 Performance Measures on Cardiac.

Clinical pathway for people with atrial fibrillation or at risk of atrial fibrillation Dr Ruth Chambers OBE LTC Priority Lead, West Midlands Academic Health.

Date of download: 7/7/2016 From: Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American.

Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.

CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation

Impact of Radial Access on Bleeding

From: Diagnosis of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American College of.

Disclosure Consultations and Honoraria Grant Support

Cardiovascular Disease

Pathways in Anticoagulation

Hypertension Update: How Low Shall We Go?

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

Cardiovascular Disease (CVD) in Texas

Mechanisms, Clinical Significance, and Prevention of Cognitive Impairment in Patients With Atrial Fibrillation Lena Rivard, MD, MSc, Paul Khairy, MD,

Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Irbedrin Group Training

Trends in Stroke Rates, Risk, and Outcomes in the United States, 1988 to 2008 Margaret C. Fang, MD, MPH, Marcelo Coca Perraillon, MA, Kaushik Ghosh, PhD,

Gregory Y.H. Lip, MD, Jonathan L. Halperin, MD, Hung-Fat Tse, MD, PhD

Self-Management of Anticoagulant Therapy in Mechanical Heart Valve Patients: A Matched Cohort Study Thomas Decker Christensen, MD, PhD, Flemming Skjøth,

Antiplatelet Therapy Use after Discharge among Acute Myocardial Infarction Patients with In-hospital Bleeding Tracy Y. Wang, MD, MHS, Lan Xiao, PhD, Karen.

When Guidelines Cause Hypertension

Blood Pressure and Outcomes in Very Old Hypertensive Coronary Artery Disease Patients: An INVEST Substudy Scott J. Denardo, MD, Yan Gong, PhD, Wilmer.

The Heart Truth Delaware Background

Appropriate Use Criteria for coronary revascularization in patients with stable ischemic heart disease: What the surgeon needs to know Harold L. Lazar,

Would it be more beneficial to take aspirin in the evening for prevention of cardiovascular diseases? Ildikó Kriszbacher, MSC, Miklós Koppán, MD, PhD,

Presentation transcript:

Current Quality of Cardiovascular Prevention for Million Hearts™ An Analysis of 147,038 Outpatients from The Guideline Advantage ™ Zubin J. Eapen, MD, MHS; Li Liang, PhD; Vincent J. Bufalino, MD; Eric D. Peterson MD, MPH; Adrian F. Hernandez, MD, MHS Duke Clinical Research Institute (Durham, NC) and Midwest Heart Specialists (Naperville, IN)

Presenter Disclosure Information DISCLOSURE INFORMATION: ZJ Eapen: none Li Liang: none VJ Bufalino: none ED Peterson: research funding from Eli Lilly & Company, Janssen Pharmaceuticals, Society of Thoracic Surgeons, American Heart Association, American College of Cardiology (significant); consulting for Boehringer Ingelheim, Janssen Pharmaceuticals Inc. (modest). AF Hernandez: research funding from Amylin Inc., Johnson & Johnson, Portola Pharmaceuticals; consulting for AstraZeneca, Johnson & Johnson, Ortho-McNeil-Janssen Pharmaceuticals, Inc., Corthera (modest).

Background Million Hearts™ is a national initiative to prevent 1 million heart attacks and strokes over 5 years by improving cardiovascular prevention. The quality of outpatient cardiovascular prevention has not been fully described.

Goals of Million Hearts Aspirin for high-risk patients A Blood pressure control B Cholesterol management C Smoking cessation S

Mechanism for contributing data Site Mapping document Site Mapping document Site Mapping document

Mechanism for contributing data Site Continuity of care record

Denominators Patients aged 18 and older with: a diagnosis of ischemic vascular disease or acute myocardial infarction A A B B C C S S

Denominators Patients aged 18 through 85 years who: have a diagnosis of hypertension whose blood pressure was adequately controlled (<140/90 mmHg) during the most recent outpatient visit A A B B C C S S

Denominators Patients aged 18 through 75 years with: a diagnosis of diabetes mellitus whose most recent LDL-C level was less than 100 mg/dL during the 12 months prior to the most recent visit A A B B C C S S

Denominators Patients aged 18 years and older who: were screened for tobacco use at least once during the 24 months prior to the most recent visit and received a tobacco cessation intervention if identified as a tobacco user A A B B C C S S

Baseline characteristics

Compliance with Million Hearts

Site-level variation in compliance BCS No. of sites % of patients

Factors associated with compliance Antiplatelet therapy for ischemic vascular disease

Blood pressure control Factors associated with compliance

Cholesterol control in diabetes Factors associated with compliance

Smoking cessation Factors associated with compliance

Limitations Quality of care may be different among practices motivated to participate in this quality improvement initiative. A significant proportion of the failure to prescribe may be due to undocumented and confounding physician impressions. Currently, there are significant challenges in standardizing EHR data for national quality improvement initiatives.

Conclusions Evaluating quality of ambulatory care across multiple practices is possible via The Guideline Advantage™, a national quality improvement program. Compliance with clinical quality measures for the Million Hearts™ initiative varies widely across outpatient practices. There are gender and racial disparities in the quality of outpatient care. Our findings identify multiple opportunities to improve the quality of outpatient care for cardiovascular prevention.

Acknowledgments This project was supported by the American Heart Association in partnership with the American Cancer Society and the American Diabetes Association This project was supported in part by grant number U19HS from the Agency for Healthcare Research and Quality. The content is solely the responsibility of the authors and does not represent the official views of the Agency for Healthcare Research and Quality.